Marcus Simmons, MD
Internal Medicine · Macon, GANPI 1770511180
Payments from drug & device makers
Across 227 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$451
- AbbVie$450
- Merck$294
- Novo Nordisk$287
- AstraZeneca$276
- Pfizer$227
- plus $2K from 29 others
What the payments were for
- Food & beverage$3,755100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 28 | $451 |
| AbbVie(2 entities) | 28 | $450 |
| Merck | 19 | $294 |
| Novo Nordisk | 15 | $287 |
| AstraZeneca | 17 | $276 |
| Pfizer | 14 | $227 |
| GSK | 12 | $202 |
| Johnson & Johnson | 13 | $173 |
| Amarin Pharma, Inc. | 10 | $152 |
| Lilly USA, LLC | 9 | $146 |
| Boehringer Ingelheim | 8 | $134 |
| Novartis | 7 | $118 |
| Abbott | 5 | $102 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Avanir Pharmaceuticals, Inc. | 4 | $60 |
| Ironwood Pharmaceuticals, Inc | 3 | $52 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Halozyme Inc | 2 | $44 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Exact Sciences | 2 | $35 |
| Antares Pharma, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 2 | $24 |
| Vifor Pharma, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 2 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$3,760 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HaegardaC1 Esterase Inhibitor | 18 | $639,866 |
| OzempicSemaglutide | 219 | $282,710 |
| EliquisApixaban | 181 | $136,033 |
| MounjaroTirzepatide | 54 | $57,636 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $55,094 |
| NucalaMepolizumab | 12 | $44,266 |
| MyrbetriqMirabegron | 48 | $35,004 |
| XareltoRivaroxaban | 34 | $28,429 |
| JardianceEmpagliflozin | 25 | $24,789 |
| EntrestoSacubitril/Valsartan | 28 | $24,451 |
| TradjentaLinagliptin | 21 | $24,277 |
| JanuviaSitagliptin Phosphate | 27 | $21,603 |
| LinzessLinaclotide | 21 | $18,798 |
| Spiriva RespimatTiotropium Bromide | 16 | $17,363 |
| FarxigaDapagliflozin Propanediol | 21 | $16,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $287 | $282,710219 claims |
| PfizerEliquis | $227 | $136,033181 claims |
| GSKTrelegy Ellipta, Nucala | $202 | $99,36062 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $134 | $66,42962 claims |
| Lilly USA, LLCMounjaro | $146 | $57,63654 claims |
| Astellas Pharma US IncMyrbetriq | $18 | $35,00448 claims |
| MerckJanuvia, Janumet | $294 | $33,67140 claims |
| AbbVieLinzess, Creon | $450 | $33,52933 claims |
| Johnson & JohnsonXarelto | $173 | $28,42934 claims |
| NovartisEntresto | $118 | $24,45128 claims |
| AstraZenecaFarxiga, Daliresp | $276 | $21,19133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Macon
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.